208 related articles for article (PubMed ID: 20019052)
1. A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.
Zhang Y; Askenazi M; Jiang J; Luckey CJ; Griffin JD; Marto JA
Mol Cell Proteomics; 2010 May; 9(5):780-90. PubMed ID: 20019052
[TBL] [Abstract][Full Text] [Related]
2. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
3. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
[TBL] [Abstract][Full Text] [Related]
4. Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.
Rocnik JL; Okabe R; Yu JC; Lee BH; Giese N; Schenkein DP; Gilliland DG
Blood; 2006 Aug; 108(4):1339-45. PubMed ID: 16627759
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Kindler T; Breitenbuecher F; Kasper S; Estey E; Giles F; Feldman E; Ehninger G; Schiller G; Klimek V; Nimer SD; Gratwohl A; Choudhary CR; Mueller-Tidow C; Serve H; Gschaidmeier H; Cohen PS; Huber C; Fischer T
Blood; 2005 Jan; 105(1):335-40. PubMed ID: 15345593
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD.
Kazi JU; Chougule RA; Li T; Su X; Moharram SA; Rupar K; Marhäll A; Gazi M; Sun J; Zhao H; Rönnstrand L
Cell Mol Life Sci; 2017 Jul; 74(14):2679-2688. PubMed ID: 28271164
[TBL] [Abstract][Full Text] [Related]
7. NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.
Rudorf A; Müller TA; Klingeberg C; Kreutmair S; Poggio T; Gorantla SP; Rückert T; Schmitt-Graeff A; Gengenbacher A; Paschka P; Baldus C; Zeiser R; Vassiliou GS; Bradley A; Duyster J; Illert AL
Blood; 2019 Jul; 134(4):383-388. PubMed ID: 31186273
[TBL] [Abstract][Full Text] [Related]
8. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
9. Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.
Chan PM
Protein Cell; 2011 Feb; 2(2):108-15. PubMed ID: 21359601
[TBL] [Abstract][Full Text] [Related]
10. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
11. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.
Arora D; Stopp S; Böhmer SA; Schons J; Godfrey R; Masson K; Razumovskaya E; Rönnstrand L; Tänzer S; Bauer R; Böhmer FD; Müller JP
J Biol Chem; 2011 Apr; 286(13):10918-29. PubMed ID: 21262971
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
13. Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.
Staudt D; Murray HC; McLachlan T; Alvaro F; Enjeti AK; Verrills NM; Dun MD
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332834
[TBL] [Abstract][Full Text] [Related]
14. FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Chougule RA; Kazi JU; Rönnstrand L
Oncotarget; 2016 Mar; 7(9):9964-74. PubMed ID: 26848862
[TBL] [Abstract][Full Text] [Related]
15. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.
Yoshimoto G; Miyamoto T; Jabbarzadeh-Tabrizi S; Iino T; Rocnik JL; Kikushige Y; Mori Y; Shima T; Iwasaki H; Takenaka K; Nagafuji K; Mizuno S; Niiro H; Gilliland GD; Akashi K
Blood; 2009 Dec; 114(24):5034-43. PubMed ID: 19808698
[TBL] [Abstract][Full Text] [Related]
16. FLT3/ITD mutation signaling includes suppression of SHP-1.
Chen P; Levis M; Brown P; Kim KT; Allebach J; Small D
J Biol Chem; 2005 Feb; 280(7):5361-9. PubMed ID: 15574429
[TBL] [Abstract][Full Text] [Related]
17. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
18. Deficiency of core fucosylation activates cellular signaling dependent on FLT3 expression in a Ba/F3 cell system.
Duan C; Fukuda T; Isaji T; Qi F; Yang J; Wang Y; Takahashi S; Gu J
FASEB J; 2020 Feb; 34(2):3239-3252. PubMed ID: 31908039
[TBL] [Abstract][Full Text] [Related]
19. The antitumor compound triazoloacridinone C-1305 inhibits FLT3 kinase activity and potentiates apoptosis in mutant FLT3-ITD leukemia cells.
Augustin E; Skwarska A; Weryszko A; Pelikant I; Sankowska E; Borowa-Mazgaj B
Acta Pharmacol Sin; 2015 Mar; 36(3):385-99. PubMed ID: 25640477
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.
Chatterjee A; Ghosh J; Ramdas B; Mali RS; Martin H; Kobayashi M; Vemula S; Canela VH; Waskow ER; Visconte V; Tiu RV; Smith CC; Shah N; Bunting KD; Boswell HS; Liu Y; Chan RJ; Kapur R
Cell Rep; 2014 Nov; 9(4):1333-48. PubMed ID: 25456130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]